Quick Answer
Cadrenal Therapeutics, Inc. reported Shares Outstanding of 2.34 million shares for fiscal year 2025.
Cadrenal Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 2.34M | +31.2% |
| 2024 | 1.78M | +105.3% |
| 2023 | 868,184 | -89.4% |
| 2022 | 8.19M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 2.06M | +66.8% | +2.6% |
| June 30, 2025 | 2.01M | -87.5% | +5.1% |
| March 31, 2025 | 1.91M | -88.1% | +7.1% |
| December 31, 2024 | 1.78M | +105.3% | +44.4% |
| September 30, 2024 | 1.23M | -90.5% | -92.3% |
| June 30, 2024 | 16.01M | +36.6% | +0.0% |
| March 31, 2024 | 16.01M | +36.6% | +1743.9% |
| December 31, 2023 | 868,184 | -89.4% | -93.3% |
- Cadrenal Therapeutics, Inc. showed an increase of +31.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s shares outstanding has declined by 71.5% (from 8.19 million shares to 2.34 million shares).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: